Investigational Drug Details
Drug ID: | D073 |
Drug Name: | Theophylline |
Synonyms: | |
Type: | small molecule |
DrugBank ID: | DB00277 |
DrugBank Description: | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. |
PubChem ID: | 2153 |
CasNo: | 58-55-9 |
Repositioning for NAFLD: | Yes |
SMILES: | CN1C2=C(NC=N2)C(=O)N(C)C1=O |
Structure: |
|
InChiKey: | ZFXYFBGIUFBOJW-UHFFFAOYSA-N |
Molecular Weight: | 180.164 |
DrugBank Targets: | Adenosine receptor A1; Adenosine receptor A2a; Adenosine receptor A2b; cAMP-specific 3',5'-cyclic phosphodiesterase 4B; cGMP-specific 3',5'-cyclic phosphodiesterase; cAMP-specific 3',5'-cyclic phosphodiesterase 4A; cGMP-inhibited 3',5'-cyclic phosphodiesterase A; Histone deacetylase 2; Copine-1; Minor histocompatibility antigen H13; Nodal modulator 1; Poly [ADP-ribose] polymerase 1; Protein RIC-3; Tubulin monoglycylase TTLL3 |
DrugBank MoA: | Theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin. |
DrugBank Pharmacology: | Theophylline, an xanthine derivative chemically similar to caffeine and theobromine, is used to treat asthma and bronchospasm. Theophylline has two distinct actions in the airways of patients with reversible (asthmatic) obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). |
DrugBank Indication: | For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis. |
Targets: | |
Therapeutic Category: | |
Clinical Trial Progress: | |
Latest Progress: |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
---|---|---|---|---|---|---|---|
L3064 | NCT00766857 | PHASE4 | COMPLETED | NO | 2009-05 | 2015-12-09 | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
---|---|---|---|---|---|---|---|
T49 | Apolipoprotein L1 | APOL1 | Target is a single protein chain | O14791 | APOL1_HUMAN | Details | |
T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
T15 | Steryl-sulfatase | STS | INHIBITOR | Hydrolase | P08842 | STS_HUMAN | Details |
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Article ID | PMID | Source | Title |
---|